These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 31992792)

  • 1. A serum metabolomics study of patients with nAMD in response to anti-VEGF therapy.
    Gao Y; Teo YCK; Beuerman RW; Wong TY; Zhou L; Cheung CMG
    Sci Rep; 2020 Jan; 10(1):1341. PubMed ID: 31992792
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Peripheral blood mononuclear cells from neovascular age-related macular degeneration patients produce higher levels of chemokines CCL2 (MCP-1) and CXCL8 (IL-8).
    Lechner J; Chen M; Hogg RE; Toth L; Silvestri G; Chakravarthy U; Xu H
    J Neuroinflammation; 2017 Feb; 14(1):42. PubMed ID: 28231837
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Optimizing Anti-VEGF Treatment Outcomes for Patients with Neovascular Age-Related Macular Degeneration.
    Wykoff CC; Clark WL; Nielsen JS; Brill JV; Greene LS; Heggen CL
    J Manag Care Spec Pharm; 2018 Feb; 24(2-a Suppl):S3-S15. PubMed ID: 29383980
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inflammatory Factors of Macular Atrophy in Eyes With Neovascular Age-Related Macular Degeneration Treated With Aflibercept.
    Sato T; Enoki T; Karasawa Y; Someya H; Taguchi M; Harimoto K; Takayama K; Kanda T; Ito M; Takeuchi M
    Front Immunol; 2021; 12():738521. PubMed ID: 34721402
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Real-life management of neovascular age-related macular degeneration (nAMD) in France: a nationwide observational study using retrospective claims data.
    Korobelnik JF; Delcourt C; Creuzot-Garcher C; Melaine A; Chassetuillier J; Lejeune A; Bénard S; Dupont-Benjamin L
    J Med Econ; 2021; 24(1):1087-1097. PubMed ID: 34420480
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-vascular endothelial growth factor for neovascular age-related macular degeneration.
    Solomon SD; Lindsley K; Vedula SS; Krzystolik MG; Hawkins BS
    Cochrane Database Syst Rev; 2019 Mar; 3(3):CD005139. PubMed ID: 30834517
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Profiling neovascular age-related macular degeneration choroidal neovascularization lesion response to anti-vascular endothelial growth factor therapy using SSOCTA.
    Told R; Reiter GS; Mittermüller TJ; Schranz M; Reumueller A; Schlanitz FG; Weigert G; Pollreisz A; Sacu S; Schmidt-Erfurth U
    Acta Ophthalmol; 2021 Mar; 99(2):e240-e246. PubMed ID: 32706171
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Metabolomics study of treatment response to conbercept of patients with neovascular age-related macular degeneration and polypoidal choroidal vasculopathy.
    Shen Y; Wang H; Xu X; Chen C; Zhu S; Cheng L; Fang J; Liu K; Xu X
    Front Pharmacol; 2022; 13():991879. PubMed ID: 36199690
    [No Abstract]   [Full Text] [Related]  

  • 9. Multimodal imaging based biomarkers predictive of early and late response to anti-VEGFs during the first year of treatment for neovascular age-related macular degeneration.
    Tarakcioglu HN; Ozkaya A; Kemer B; Taskapili M
    J Fr Ophtalmol; 2019 Jan; 42(1):22-31. PubMed ID: 30578008
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enhanced depth imaging of the choroid in patients with neovascular age-related macular degeneration treated with anti-VEGF therapy versus untreated patients.
    Rahman W; Chen FK; Yeoh J; da Cruz L
    Graefes Arch Clin Exp Ophthalmol; 2013 Jun; 251(6):1483-8. PubMed ID: 23160538
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacogenetic associations with vascular endothelial growth factor inhibition in participants with neovascular age-related macular degeneration in the IVAN Study.
    Lotery AJ; Gibson J; Cree AJ; Downes SM; Harding SP; Rogers CA; Reeves BC; Ennis S; Chakravarthy U;
    Ophthalmology; 2013 Dec; 120(12):2637-2643. PubMed ID: 24070809
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety of monoclonal antibodies and related therapeutic proteins for the treatment of neovascular macular degeneration: addressing outstanding issues.
    Ziemssen F; Sobolewska B; Deissler H; Deissler H
    Expert Opin Drug Saf; 2016 Jan; 15(1):75-87. PubMed ID: 26568279
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Different Outcomes of Anti-VEGF Treatment for Neovascular AMD according to Neovascular Sutypes and Baseline Features: 2-Year Real-Life Clinical Outcomes.
    Arrigo A; Saladino A; Aragona E; Mercuri S; Introini U; Bandello F; Parodi MB
    Biomed Res Int; 2021; 2021():5516981. PubMed ID: 34124243
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Photodynamic therapy in VEGF inhibition non-responders-Pharmacogenetic study in age-related macular degeneration assessed with swept-source optical coherence tomography.
    Teper SJ; Nowinska A; Pilat J; Wylegala E
    Photodiagnosis Photodyn Ther; 2016 Mar; 13():108-113. PubMed ID: 26780119
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Real-Life Experience and Predictors of Visual Outcomes with Intravitreal Brolucizumab Switch for Treatment of Neovascular Age-Related Macular Degeneration.
    Cavalleri M; Tombolini B; Sacconi R; Gatta G; Valeri R; Bandello F; Querques G
    Ophthalmologica; 2023; 246(2):158-168. PubMed ID: 37040734
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Real world evidence of use of anti-VEGF therapy in Denmark.
    Vorum H; Olesen TK; Zinck J; Størling Hedegaard M
    Curr Med Res Opin; 2016 Dec; 32(12):1943-1950. PubMed ID: 27494692
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Use of Vascular Endothelial Growth Factor Inhibitors and Complementary Treatment Options in Polypoidal Choroidal Vasculopathy: A Subtype of Neovascular Age-Related Macular Degeneration.
    Teo KYC; Gillies M; Fraser-Bell S
    Int J Mol Sci; 2018 Sep; 19(9):. PubMed ID: 30177632
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Analysis of the association between CFH Y402H polymorphism and response to intravitreal ranibizumab in patients with neovascular age-related macular degeneration (nAMD).
    Mohamad NA; Ramachandran V; Ismail P; Mohd Isa H; Chan YM; Ngah NF; Md Bakri N; Ching SM; Hoo FK; Wan Sulaiman WA; Inche Mat LN; Hazmi Mohamed M
    Bosn J Basic Med Sci; 2018 Aug; 18(3):260-267. PubMed ID: 29579408
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predictors of good visual outcomes in patients with neovascular age-related macular degeneration in daily practice.
    Prieto-Del-Cura M; Villafruela-Güemes I; Recio-Gamo E; Sastre-Ibañez M; Fuentes-Ferrer ME
    J Fr Ophtalmol; 2020 Dec; 43(10):989-995. PubMed ID: 33081995
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Defining Nonadherence and Nonpersistence to Anti-Vascular Endothelial Growth Factor Therapies in Neovascular Age-Related Macular Degeneration.
    Okada M; Wong TY; Mitchell P; Eldem B; Talks SJ; Aslam T; Daien V; Rodriguez FJ; Gale R; Barratt J; Finger RP; Loewenstein A
    JAMA Ophthalmol; 2021 Jul; 139(7):769-776. PubMed ID: 34081099
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.